Shadi Barbu, MD
Neurology · Phoenix, AZNPI 1841678802
Payments from drug & device makers
Across 155 payments — averaging $50.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Boston Scientific$1K
- Amneal Pharmaceuticals LLC$447
- AbbVie$301
- Revance Therapeutics, Inc.$287
- Teva Pharmaceuticals USA, Inc.$186
- plus $741 from 13 others
What the payments were for
- Travel & lodging$4,28855%
- Food & beverage$3,51245%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 51 | $4,712 |
| Boston Scientific | 10 | $1,127 |
| Amneal Pharmaceuticals LLC | 34 | $447 |
| AbbVie | 16 | $301 |
| Revance Therapeutics, Inc. | 6 | $287 |
| Teva Pharmaceuticals USA, Inc. | 8 | $186 |
| Acadia Pharmaceuticals Inc | 3 | $141 |
| Kyowa Kirin, Inc. | 5 | $110 |
| Biogen | 4 | $87 |
| MDD US Operations, LLC | 4 | $86 |
| Neurocrine Biosciences, Inc. | 3 | $84 |
| Merz Pharmaceuticals, LLC | 2 | $56 |
| Acorda Therapeutics, Inc | 2 | $39 |
| Averitas Pharma Inc. | 1 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| GE HealthCare | 1 | $24 |
| Avion Pharmaceuticals | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| UCB, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCEPT PC BRAINSENSE$2,414
- ACTIVA$963
- VERCISE$649
- GENERAL VASCULAR ACCESS$241
- DAXXIFY$143
- NUPLAZID$102
How this compares
$7,801 in reported general payments places this provider in the 55th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 95 | $544,939 |
| RytaryCarbidopa/Levodopa | 115 | $215,605 |
| AustedoDeutetrabenazine | 12 | $203,882 |
| IngrezzaValbenazine Tosylate | 12 | $103,314 |
| GocovriAmantadine Hcl | 32 | $96,972 |
| DuopaCarbidopa/Levodopa | 15 | $89,936 |
| Austedo XrDeutetrabenazine | 13 | $67,553 |
| InbrijaLevodopa | 12 | $66,138 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 889 | $28,188 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 300 | $20,706 |
| NeuproRotigotine | 11 | $19,183 |
| Rasagiline Mesylate | 38 | $11,222 |
| AmantadineAmantadine Hcl | 184 | $9,424 |
| LinzessLinaclotide | 12 | $6,404 |
| Entacapone | 26 | $5,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $141 | $544,93995 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $186 | $271,43525 claims |
| Amneal Pharmaceuticals LLCRytary | $447 | $215,605115 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $84 | $103,31412 claims |
| MDD US Operations, LLCGocovri | $86 | $96,97232 claims |
| AbbVieDuopa, Linzess | $301 | $96,34027 claims |
| Acorda Therapeutics, IncInbrija | $39 | $66,13812 claims |
| UCB, Inc.Neupro | $15 | $19,18311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- David WeidmanPhoenix$7.4M
- Stephen FlitmanPhoenix$4.4M
- Barry HendinPhoenix$4.4M
- Jeremy ShefnerPhoenix$3M
- Danielle CabralPhoenix$2.8M
- Suraj MuleyPhoenix$2.8M
- Todd SchwedtPhoenix$2.8M
- Todd LevinePhoenix$2.7M
- Anna BurkePhoenix$2.2M
- Maria OspinaPhoenix$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.